DB:38I

Stock Analysis Report

Executive Summary

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Intellia Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 38I's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.3%

38I

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-24.9%

38I

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 38I underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 38I underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

38IIndustryMarket
7 Day-7.3%11.3%7.1%
30 Day-3.2%-8.0%-20.0%
90 Day-19.1%-22.7%-26.1%
1 Year-24.9%-24.9%-4.9%-5.1%-15.0%-17.5%
3 Year-14.6%-14.6%17.7%16.4%-18.8%-25.8%
5 Yearn/a-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Intellia Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?

2.22x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 38I's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 38I's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 38I is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 38I is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 38I's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 38I is good value based on its PB Ratio (2.2x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-12.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 38I is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 38I is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 38I is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 38I's revenue (22.4% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 38I's revenue (22.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 38I's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Intellia Therapeutics performed over the past 5 years?

-38.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 38I is currently unprofitable.

Growing Profit Margin: 38I is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 38I is unprofitable, and losses have increased over the past 5 years at a rate of -38.5% per year.

Accelerating Growth: Unable to compare 38I's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 38I is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 38I has a negative Return on Equity (-36.88%), as it is currently unprofitable.


Next Steps

Financial Health

How is Intellia Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 38I's short term assets ($289.5M) exceed its short term liabilities ($35.6M).

Long Term Liabilities: 38I's short term assets ($289.5M) exceed its long term liabilities ($28.8M).


Debt to Equity History and Analysis

Debt Level: 38I is debt free.

Reducing Debt: 38I has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 38I has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 38I's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 38I has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 38I has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of -50.2% each year.


Next Steps

Dividend

What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 38I's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 38I's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 38I's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 38I's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 38I's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

John Leonard (62yo)

2.17s

Tenure

US$9,708,330

Compensation

Dr. John M. Leonard, M.D., has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Leonard has been the President and Chief Executive Officer  ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD9.71M) is above average for companies of similar size in the German market ($USD1.40M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Leonard
President2.17yrsUS$9.71m1.04% $5.7m
Glenn Goddard
Executive VP & CFO1.42yrsUS$2.34mno data
Andrew Schiermeier
Executive VP & COO1.17yrsUS$2.93m0.020% $110.9k
José Rivera
Executive VP5.67yrsUS$2.65m0.55% $3.0m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mno data
Rachel Haurwitz
Co-Founder5.83yrsUS$311.57kno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Board4.92yrsno datano data
Derrick Rossi
Founder & Member of Scientific Advisor Board4.92yrsno datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data

3.9yrs

Average Tenure

49yo

Average Age

Experienced Management: 38I's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
John Leonard
President2.17yrsUS$9.71m1.04% $5.7m
Nessan Bermingham
Founder & Member of Scientific Advisor Boardno dataUS$11.27mno data
Andrew May
Founder and Member of Scientific Advisor Boardno datano datano data
Jennifer Doudna
Founder & Member of Scientific Advisor Board4.92yrsno datano data
Derrick Rossi
Founder & Member of Scientific Advisor Board4.92yrsno datano data
Rodolphe Barrangou
Founder & Member of Scientific Advisor Boardno datano datano data
Luciano Marraffini
Founder & Member of Scientific Advisor Boardno datano datano data
Erik Sontheimer
Founder & Member of Scientific Advisor Boardno datano datano data
Jean-Francois Formela
Independent Director5.83yrsUS$351.08kno data
Frank A. G. Verwiel
Independent Chairman of the Board0.083yrUS$397.08kno data

4.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 38I's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.


Top Shareholders

Company Information

Intellia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intellia Therapeutics, Inc.
  • Ticker: 38I
  • Exchange: DB
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$602.052m
  • Listing Market Cap: US$542.990m
  • Shares outstanding: 50.51m
  • Website: https://www.intelliatx.com

Number of Employees


Location

  • Intellia Therapeutics, Inc.
  • 40 Erie Street
  • Suite 130
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTLANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2016
38IDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2016
0JBULSE (London Stock Exchange)YesCommon StockGBUSDMay 2016
38IBRSE (Berne Stock Exchange)YesCommon StockCHCHFMay 2016

Biography

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:58
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.